Abstract: The present invention provides a composite comprising graphene, a conjugated porous organic polymer and a metalloprotein and to methods of making the composite. The invention also relates to articles (e.g. to an electrode) comprising the composite and to uses of the composite, e.g. in heterogeneous catalysis of oxygen reduction reactions, and in oxygen sensing.

Abstract: The present invention provides a composite comprising graphene, a conjugated porous organic polymer and a metalloprotein and to methods of making the composite. The invention also relates to articles (e.g. to an electrode) comprising the composite and to uses of the composite, e.g. in heterogeneous catalysis of oxygen reduction reactions, and in oxygen sensing.

Abstract: Pharmaceutical formulations are described for use in the treatment of pulmonary arterial hypertension (PAH). The formulations comprise polymeric nanoparticles encapsulated within crosslinked polymeric hydrogel microparticles, wherein the polymeric nanoparticles carry a therapeutic agent suitable for treatment of PAH loaded within them (for example, prostacyclin synthetic analogs, PPAR ? agonists and NO donors). Preferred formulations are inhalable, dry powder pharmaceutical formulations, which are able to swell on administration to the lungs of a patient.

Abstract: Therapeutic formulations are described for use in the treatment of chronic obstructive pulmonary disease, bronchial asthma, cystic fibrosis, chlorine inhalation, influenza and acute myocardial infarction. The formulations comprise polymeric nanoparticles or polymeric nanoparticles encapsulated within cross-linked polymeric hydrogel microparticles, wherein the polymeric nanoparticles carry a therapeutic agent suitable for treatment of chronic obstructive pulmonary disease, bronchial asthma, cystic fibrosis, chlorine inhalation, influenza, acute myocardial infarction and heart failure. Preferred formulations are inhalable, dry powder therapeutic formulations, which are able to swell on administration to the lungs of a patient.

Abstract: The invention involves bioresorbable stents which elute nitric oxide (NO). The stent is comprised of three main key design elements: a bioresorbable scaffold, a bioresorbable polymeric coating layer(s), and NO-releasing nanoparticles incorporated in the bioresorbable polymeric coating layer, and optionally also in the scaffold. The NO-releasing nanoparticles are made of nontoxic biocompatible and biodegradable materials; for example a chitosan polymer and optionally a sugar.

Abstract: Therapeutic formulations are described for use in the treatment of chronic obstructive pulmonary disease, bronchial asthma, cystic fibrosis, chlorine inhalation, influenza and acute myocardial infarction. The formulations comprise polymeric nanoparticles or polymeric nanoparticles encapsulated within cross-linked polymeric hydrogel microparticles, wherein the polymeric nanoparticles carry a therapeutic agent suitable for treatment of chronic obstructive pulmonary disease, bronchial asthma, cystic fibrosis, chlorine inhalation, influenza, acute myocardial infarction and heart failure. Preferred formulations are inhalable, dry powder therapeutic formulations, which are able to swell on administration to the lungs of a patient.

Abstract: Described herein are pharmaceutical formulations for the treatment of hypercholesterolemia, comprising nanoparticles having a polymeric hydrophobic core which is associated with an inhibitor of PCSK9. The inhibitor may be EGF-A, EGF-B, or an siRNA. Preferred polymers include chitosan. The nanoparticle may further include a hydrophilic shell coating the core.

Abstract: Disclosed herein are bioresorbable stents which elute nitric oxide (NO). The stent is comprised of three main key design elements: a bioresorbable scaffold, a bioresorbable polymeric coating layer(s), and NO-releasing nanoparticles incorporated in the bioresorbable polymeric coating layer, and optionally also in the scaffold. The NO-releasing nanoparticles are made of nontoxic biocompatible and biodegradable materials; for example a chitosan polymer and optionally a sugar.

Abstract: Provided is a peptide and a hydrogel prepared therefrom. The peptide comprises the sequence Gly-(A)-(Gly-X-Y)m-M-(Gly-X-Y)n-Gly-(B)-Gly, wherein A and B are telopeptides, X and Y are any amino acid, m and n are integers of at least 3 and M is a receptor binding sequence. Artificial collagen derived from the peptide of the invention provides an alternative to the use of animal- or human-derived collagen in industrial, biological and biomedical applications.

Abstract: A ventricular assist device comprising a housing defining an interior space, at least two ports opening into said interior space, and at least one pump for pumping blood between the ports through said interior space, the ports and interior space providing a continuous blood flow path that is not interrupted by valves.

Abstract: Pharmaceutical formulations are described for use in the treatment of pulmonary arterial hypertension (PAH). The formulations comprise polymeric nanoparticles encapsulated within crosslinked polymeric hydrogel microparticles, wherein the polymeric nanoparticles carry a therapeutic agent suitable for treatment of PAH loaded within them (for example, prostacyclin synthetic analogs, PPAR ? agonists and NO donors). Preferred formulations are inhalable, dry powder pharmaceutical formulations, which are able to swell on administration to the lungs of a patient.

Abstract: A method of forming a matrix of aligned nanofibres of elevated pore size and porosity comprises spraying a polymer solution towards a rotating drum so as to form nanofibres which are collected on the drum. The matrix can be used to form artificial tissue by removing the matrix from the drum, depositing cells onto the matrix and allowing the cells to form artificial tissue. Such artificial tissue finds use in the treatment of disease or damaged tissue, and in particular in the treatment of cardiovascular disease.

Abstract: A ventricular assist device comprising a housing defining an interior space, at least two ports opening into said interior space, and at least one pump for pumping blood between the ports through said interior space, the ports and interior space providing a continuous blood flow path that is not interrupted by valves.

Abstract: A ventricular assist device comprising a housing defining an interior space, at least two ports opening into said interior space, and at least one pump for pumping blood between the ports through said interior space, the ports and interior space providing a continuous blood flow path that is not interrupted by valves.